FierceBiotech

Cyrano Therapeutics is savoring a phase 2 victory. With the [...]

The FDA has rejected a rare blood disease candidate from [...]

Just as a disciplined soccer player might pass on a [...]

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes [...]

With sales of Immunocore’s melanoma medicine steadily ticking up, an [...]

Messenger RNA specialist Moderna’s R&D spend sunk by nearly a [...]

Ultragenyx’s employees were already braced for changes as the biopharma [...]

Sanofi is replacing CEO Paul Hudson with Merck KGaA leader [...]

After scrapping one portion of the trial, Lundbeck’s intravenous monoclonal [...]

Just months after laying off a quarter of its workforce [...]